Selenium supplementation in radiotherapy patients: do we need to measure selenium levels in serum or blood regularly prior radiotherapy?

Radiation Oncology

Jan Kriz³  Jutta Huebner⁴  Jens Buentzel⁷  Klaus Kisters⁵  Lutz Schomburg²  Oliver Micke⁶  Ralph Muecke¹ 

[1] Department of Radiotherapy and Radiation Oncology, Ruhr University Bochum, Bochum, Germany;Institute for Experimental Endocrinology, Charité Berlin, Germany;Department of Radiotherapy and Radiation Oncology, Münster University Hospital, Münster, Germany;Working Group Integrative Oncology, German Cancer Society, Berlin, Germany;Department of Internal Medicine, St. Anna Hospital, Herne, Germany;Department of Radiotherapy and Radiation Oncology, Franziskus Hospital, Bielefeld, Germany;Department of Otolaryngology, Südharz Hospital, Nordhausen, Germany

关键词: Radiotherapy;    Selenoproteins;    Clinical studies;    Supplementation;    Selenium;   

Others  :  1150576
DOI  :  10.1186/s13014-014-0289-0

 received in 2014-09-30, accepted in 2014-12-04,  发布年份 2014

【 摘 要 】

Considering the review by Puspitasari and colleagues, an additional discussion of the endpoints of the Se supplementation studies described would be helpful. In our view, selenium can safely be given to selenium-deficient cancer patients prior to and during radiotherapy. Therefore, in order to help the radiation oncologist in decision making, we strongly advocate to determine the selenium status prior to and during a potential adjuvant selenium supplementation, e.g. when trying to ease the side-effects of radiation treatment or in the aftercare situation when the selenium status may become insufficient.

【 授权许可】

   
2014 Muecke et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Puspitasari IM, Abdulah R, Yamazaki C, Kameo S, Nakano T, Koyama H: Updates on clinical studies of selenium supplementation in radiotherapy. Radiat Oncol 2014, 9:125. BioMed Central Full Text
• [2]Meyer HA, Endermann T, Stephan C, Stoedter M, Behrends T, Wolff I, Jung K, Schomburg L: Selenoprotein P Status Correlates to Cancer-Specific Mortality in Renal Cancer Patients. PLoS One 2012, 7:e46644.
• [3]Xia Y, Hill KE, Byrne DW, Xu J, Burk RF: Effectiveness of selenium Supplements in a low-selenium area of China. Am J Clin Nutr 2005, 81:829-834.
• [4]Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW: Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol Biomarkers Prev 2006, 15:804-810.
• [5]Persson-Moschos M, Alfthan G, Akesson B: Plasma selenoprotein P levels of healthy males in different selenium status after oral supplementation with different forms of selenium. Eur J Clin Nutr 1998, 52:363-367.
• [6]Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, Goldson AJ, Broadley MR, Motley AK, Fairweather-Tait SJ: Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2010, 91:923-931.
• [7]Muecke R, Schomburg L, Buentzel J, Kisters K, Micke O: Blood selenium Status in tumor patients: Omnia sunt venena, nihil est sine veneno. Sola dosis facit venenum. Trace Elem Electrolytes 2010, 27:181-182.
• [8]Muecke R, Schomburg L, Buentzel J, Kisters K, Micke O: Selenium or no selenium-that is the question in tumor patients: a new controversy. Integr Cancer Ther 2010, 9:136-141.
• [9]Bleys J, Navas-Acien A, Guallar E: Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 2008, 168:404-410.
• [10]Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston MR, Goodman G, Clamon G, Okawara G, Marks R, Frechette E, McCaskill-Stevens W, Lippman SM, Ruckdeschel J, Khuri FR: Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non-Small- Cell LungCancer: ECOG 5597. J Clin Oncol 2013, 31(33):4179-4187.
• [11]Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, et al.: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2009, 301:39-51.
• [12]Muecke R, Schomburg L, Glatzel M, Bernd-Skorka R, Baaske D, Reichl B, Buentzel J, Kundt G, Prott FJ, De Vries A, Stoll G, Kisters K, Bruns F, Schaefer U, Willich N, Micke O: Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 2010, 70:828-835.